Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec
Halozyme’s offer comes as Evotec deals with several business setbacks and a languishing stock price. Earlier this year, Evotec implemented a cost-saving corporate restructuring.